pre-IPO PHARMA

COMPANY OVERVIEW

Aqualung is an early stage biotech company developing immune-focused therapeutic antibodies for patients suffering from disorders characterized by acute and chronic lung, and systemic inflammation. Incorporated in 2016 and led by a physician scientist, Aqualung's science-driven approach led them to the identification of nicotinamide phosphoribosyltransferase (NAMPT) and other key proteins expressed in both acute and chronic inflammatory diseases. The pipeline of ALT is designed to help in a range of diseases characterized by unchecked local and systemic inflammation: Acute Respiratory Distress Syndrome (ARDS), Ventilator- and Radiation-Induced Lung Injuries, Prostate Cancer, Pulmonary Hypertension, Pulmonary Fibrosis and Chorioamnionitis. These conditions have a significant unmet medical need and many exhibit significant morbidity and mortality.


LOCATION

  • Tucson, AZ, USA

  • THERAPEUTIC AREAS

  • Fibrotic DIsease
  • Oncology
  • Respiratory Disease

  • WEBSITE

    https://www.aqualungtherapeutics.com


    CAREER WEBSITE

    None


    SOCIAL MEDIA


    INVESTORS



    PRESS RELEASES


    Dec 19, 2022

    NAMPT (Nicotinamide Phosphoribosyltransferase) Inhibitors Markets, 2040 with Profiles of Antengene Therapeutics, Aqualung Therapeutics, Karyopharm Therapeutics, OncoTartis, and Onxeo


    Dec 5, 2019

    Aqualung Therapeutics Corporation To Present New Data At Biotech Showcase Investor Conference


    Aug 20, 2019

    Aqualung Therapeutics Corporation Receives $225 Thousand Dollar National Institute of Health (NIH) Grant to Establish Biomarker Panel for Patients with Acute Respiratory Distress Syndrome


    Jun 5, 2019

    Aqualung Therapeutics Corporation Receives A $1.7 Million National Institute Of Health (NIH) Fastrack Award To Develop An Novel Immune-Based Therapeutic Antibody For Critically Ill Patients With Acute Lung Injury


    For More Press Releases


    Google Analytics Alternative